Previous 10 | Next 10 |
home / stock / kykof / kykof news
The European Union drug regulator's human medicines committee has recommended extending the indication of Koywa Kirin's (OTCPK:KYKOF) Crysvita medicine, according to the highlights of their latest meeting. Crysvita is manufactured by the Japanese pharmaceutical company and distributed by U.S....
Japan's Kyowa Kirin (OTCPK:KYKOF) is thinking of selling certain international assets which could bring in $1B, Bloomberg News reported citing people with knowledge of the matter. The company intends to explore the sale of some assets of its Kyowa Kirin International unit and has hired a...
The shares of MEI Pharma (NASDAQ:MEIP) are trading lower in the premarket Monday after the clinical-stage biotech disclosed that the company had made errors in the revenue recognition for its collaboration with Japanese drugmaker, Kyowa Kirin Co., Ltd (OTCPK:KYKOF). As a result, revenue was o...
Clinical-stage biotech, MEI Pharma (NASDAQ:MEIP -59.2%) has recorded the biggest intraday loss in over seven years as Wall Street reacts to the regulatory setback for the company’s cancer medication, zandelisib developed in partnership with Kyowa Kirin (OTCPK:KYKOF). With FDA requiring...
Kyowa Kirin Co., Ltd. press release (OTCPK:KYKOF): FY GAAP EPS of ¥97.39. Revenue of ¥352.25B (+10.6% Y/Y). For further details see: Kyowa Kirin Co., Ltd. GAAP EPS of ¥97.39, revenue of ¥352.25B
MEI Pharma (NASDAQ:MEIP) and Kyowa Kirin (OTCPK:KYKOF) gains 10.2% premarket after announcing that the Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective ...
The following slide deck was published by Kyowa Kirin Co., Ltd. in conjunction with this event. For further details see: Kyowa Kirin (KYKOF) Investor Presentation - Slideshow
Kyowa Kirin Co., Ltd. (OTCPK:KYKOF): Q2 GAAP EPS ¥46.65. Revenue of ¥165.02B (+4.6 Y/Y). Press Release For further details see: Kyowa Kirin reports Q2 results
The following slide deck was published by Kyowa Kirin Co., Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Kyowa Kirin Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation
Early indications show that Kyowa Kirin has a blockbuster drug with KHK4083, a treatment for severe atopic dermatitis (eczema). Phase 2 trials have shown encouraging results and the agreement to jointly develop and commercialize the drug with Amgen is a positive signal. With both ...
News, Short Squeeze, Breakout and More Instantly...
Kyowa Hakko Kogyo Company Name:
KYKOF Stock Symbol:
OTCMKTS Market:
TOKYO , Jan. 6, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto , "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patie...